More than they need. The United States wants to share the Astrogeneca vaccine

The White House told Andhra Pradesh on Monday that the vaccine would be released by the United States soon after the completion of the federal security test. 60 million taxes could be released on exports in the coming months. It is not yet clear which countries they will go to.

The situation abroad is currently evolving so that the US can finally make the three Govt-19 vaccines it already uses. These are fabrics from Pfizer / Bioendech, Moderna and Johnson & Johnson. Until recently, the use of the latter vaccine was fraught with complications with rare but severe side effects.

“Given the strong portfolio of already existing Food and Drug Administration (FDA) based vaccines in the United States and the fact that astrogenesis is not approved for use in the United States, we do not need vaccines in the next few months,” he told Andhra Pradesh. White House Corona virus coordinator Jeff Giants. “That is why the United States is considering sharing the benefits of Astrogene with other countries.”

According to the AP, about ten million doses could be released in a few weeks. These modules are already manufactured and subject to FDA quality control. A further 50 million blocks are in various stages of production, which may be available for export in May or June.

However, no final decision has been made as to who will be vaccinated. The United States decided last month to hand over about four million doses to Mexico and Canada, and both countries have asked the U.S. government for more.

Washington is under a lot of pressure in this regard because, as already mentioned, the AstraZeneca vaccine is not yet approved in the country. So the country gets useless benefits, while they can be used in neighboring countries or in Europe.

AstraZeneca has problems only in Europe, and the European Commission has sued the company for non-compliance with the contract to supply the vaccine. A spokesman for the European Union (EU) said in a statement on Monday that it wanted to ensure that goods were delivered to member states as soon as possible. The company later said in a statement that it had not breached the contract and would defend itself in court.

Last year, the European Union signed an agreement with a British-Swedish company, according to which AstraZeneca plans to deliver a total of 300 million doses of the vaccine to 27 states by the end of June. However, meeting the conditions in the first months of this year appeared to be an issue, with the gap between expectations and reality widening, according to Reuters in March.

The company says it does not have sufficient production capacity and must first meet the terms of the agreement with Great Britain, which ended in London before Brussels. However, the commission was not satisfied with the explanations and sent a letter to the company a month ago seeking a solution. However, he did not receive a satisfactory response within the specified time.